Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD985 plus Paclitaxel in Metastatic Cancer
NCT04602117Phase 1Withdrawn
- Sponsor
- Quantum Leap Healthcare Collaborative
- Start
- Jul 2021
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trastuzumab duocarmazine in metastatic solid tumor and breast cancer, sponsored by Quantum Leap Healthcare Collaborative. Primary endpoints: Common Toxicity Criteria for Adverse Events at 12 months, Clinical Benefit Rate at 6 months and 1 more. Planned start Jul 2021; status: withdrawn.
02
Drugs
trastuzumab duocarmazine
03
Conditions
metastatic solid tumorbreast cancer
Beyond the preview
Go deeper on NCT04602117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602117.